Glycogen storage disease type 4 (GSD IV)
Overview
Glycogen storage disease type 4 (GSD IV), also known as Andersen disease, is a rare inherited metabolic disorder caused by a shortage of an enzyme needed to properly structure glycogen, leading to a toxic buildup of abnormal sugar molecules in the body's tissues. You can read more about the condition on the MedlinePlus Genetics guide.
Symptoms
Severe hypotonia:Profoundly low muscle tone ("floppy baby" syndrome) in congenital subtypes
Cardiomyopathy: Weakened or dilated heart muscle leading to potential heart failure.
Respiratory failure: Weakened breathing muscles causing early mortality in severe infant presentations.
Neurogenic bladder: Urinary urgency, frequency, or incontinence usually appearing after age 40.
Spastic paraparesis: Progressive leg stiffness, weakness, and difficulty walking.Peripheral neuropathy: Numbness, tingling, or reduced sensation in the extremities.
Causes
GBE1 Gene Mutations: Changes or mutations in the GBE1 gene (located on chromosome 3p12) disrupt the normal instructions for making the glycogen branching enzyme.
Autosomal Recessive Inheritance: A patient must inherit one mutated GBE1 gene from each carrier parent to develop the disease. Parents who carry a single copy of the mutated gene are typically unaffected.
Enzyme Deficiency: Without enough working branching enzyme, the body cannot add proper branch points into growing glycogen molecules.
Polyglucosan Formation: Instead of normal branched glycogen, the body produces long, linear, and poorly soluble sugar chains resembling amylopectin.
Cell Damage: These abnormal chains clump together inside cells to form toxic deposits called polyglucosan bodies, which damage tissues—most severely in the liver, muscles, heart, and nervous system.
Diagnosis
Molecular Genetic Testing: Confirms the diagnosis by finding two pathogenic (disease-causing) variants in the GBE1 gene.
Enzyme Assay: Measures glycogen branching enzyme activity in skin fibroblasts, liver tissue, muscle tissue, or leukocytes to prove a reduction or deficiency.
Tissue Biopsy and Histopathology: Examines liver or muscle tissue samples under a microscope to find abnormal, poorly branched glycogen deposits known as polyglucosan bodies.
Clinical Evaluation: Assesses symptoms like an enlarged liver, failure to thrive in infants, or progressive muscle weakness in older individuals.
Treatment
Dietary optimization: Focuses on maintaining stable blood sugar and reducing the liver glycogen burden through frequent meals and a carbohydrate-restricted, high-protein diet.
Supportive monitoring: Regular evaluations by specialists—including hepatologists for liver function, cardiologists for heart health, and neurologists for muscle weakness—are essential.
Symptom management: Treatments like diuretics or medications may be used to address complications such as fluid buildup (ascites) or heart failure.
Liver transplant timing: Must be performed before advanced systemic damage occurs, particularly cardiomyopathy (heart muscle disease), which can worsen post-transplant.
Combined organ transplant: If significant heart involvement is already present, a combined heart and liver transplant may be necessary for survival.
Investigational research: Scientists continue to study experimental approaches like adeno-associated virus–mediated gene transfer to help clear abnormal glycogen accumulation throughout the body.
Type of Doctor Department : Hepatologist / Gastroenterologist ,a Medical Geneticist
.jpg)
Comments
Post a Comment